{
    "body": "What is the mechanism of action of anticoagulant medication Dabigatran?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20589316", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22388002", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22480286", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21666370", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23466964", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23031622", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19888525", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16637459", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18425569", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21988948", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21526168", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20888031"
    ], 
    "ideal_answer": [
        "Dabigatran is orally administered, reverisble direct and competetive inhibitor of both free and bouded thrombin."
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504", 
        "http://www.biosemantics.org/jochem#4242811"
    ], 
    "type": "summary", 
    "id": "51485a4dd24251bc0500002a", 
    "snippets": [
        {
            "offsetInBeginSection": 161, 
            "offsetInEndSection": 313, 
            "text": "Dabigatran etexilate is a novel oral direct thrombin inhibitor, which provides stroke risk reduction for patients with nonvalvular atrial fibrillation. ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23031622", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 455, 
            "offsetInEndSection": 584, 
            "text": "Dabigatran is a potent reversible, competitive direct thrombin inhibitor which is available as the prodrug, Dabigatran etexilate.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22480286", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 423, 
            "offsetInEndSection": 716, 
            "text": "The recently introduced oral direct thrombin antagonist, dabigatran, has been shown in phase III clinical trials to be noninferior in efficacy to warfarin for the prevention of thromboembolic events in patients with atrial fibrillation, as well as in treatment of acute venous thromboembolism.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21988948", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 465, 
            "offsetInEndSection": 669, 
            "text": "Dabigatran is an oral, reversible direct thrombin inhibitor approved in Europe and in several other countries for the prevention of venous thromboembolism after elective knee and hip replacement surgery. ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21666370", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 886, 
            "offsetInEndSection": 988, 
            "text": "Dabigatran etexilate is a direct thrombin inhibitor that inhibits both free and fibrin-bound thrombin.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20888031", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 249, 
            "offsetInEndSection": 395, 
            "text": "Direct inhibitors of FXa (rivaroxaban), FVIIa (BMS-593214), thrombin (dabigatran, argatroban) and FXIa (BMS-262084) were included for comparison. ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20589316", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 958, 
            "offsetInEndSection": 1196, 
            "text": "Two agents, the direct thrombin inhibitor dabigatran and the direct Factor Xa inhibitor rivaroxaban, have recently been approved in the EU and several other countries for the prevention of VTE after total hip or knee replacement surgery. ", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19888525", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 702, 
            "offsetInEndSection": 776, 
            "text": "The direct thrombin inhibitor dabigatran is farthest along in development.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18425569", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1742, 
            "offsetInEndSection": 1950, 
            "text": "Lastly, inhibitors of thrombin activity are composed of either indirect (UFH, LMWH), or direct thrombin (FIIa) inhibitors including: hirudin, argatroban, melagatran, ximelagatran, dabigatran, and bivalirudin.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16637459", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 334, 
            "text": "The effect of the oral direct activated factor X (factor Xa) inhibitor apixaban on tissue factor-induced thrombin generation in human plasma was investigated in vitro using the calibrated automated thrombogram (CAT) method and compared with the oral direct factor Xa inhibitor rivaroxaban and the direct thrombin inhibitor dabigatran.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466964", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 538, 
            "offsetInEndSection": 780, 
            "text": "The DTI dabigatran etexilate was recently shown to provide superior risk reduction to warfarin for stroke and systemic embolism for patients with nonvalvular AF and recently gained US Food and Drug Administration approval for this indication.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22388002", 
            "endSection": "sections.0"
        }
    ]
}